This company has been acquired
BELLUS Health Future Growth
Future criteria checks 2/6
BELLUS Health is forecast to grow earnings and revenue by 46.1% and 69% per annum respectively while EPS is expected to grow by 41.4% per annum.
Key information
46.1%
Earnings growth rate
41.4%
EPS growth rate
Biotechs earnings growth | 27.6% |
Revenue growth rate | 69.0% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 16 Jun 2023 |
Recent future growth updates
No updates
Recent updates
Bellus: Expected Phase 3 Start Makes This A Long-Term Play
Sep 07BELLUS details late-stage plans for cough candidate after FDA meeting
Jul 12BELLUS Proof Of Data In Chronic Cough Using BLU-5937 Brings Hope To Patients
Dec 14Bellus Health - Betting Big On Chronic Cough Treatment
Aug 27BELLUS Health EPS misses by $0.06
May 10BELLUS Health establishes $50M at-the-market facility
Dec 23Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2025 | 40 | -147 | -110 | -64 | 3 |
12/31/2024 | 0 | -141 | -130 | -127 | 3 |
12/31/2023 | 0 | -117 | -125 | -101 | 2 |
3/31/2023 | 0 | -87 | -89 | -89 | N/A |
12/31/2022 | 0 | -76 | -77 | -77 | N/A |
9/30/2022 | 0 | -73 | -68 | -68 | N/A |
6/30/2022 | 0 | -71 | -64 | -64 | N/A |
3/31/2022 | 0 | -70 | -60 | -60 | N/A |
12/31/2021 | 0 | -71 | -61 | -61 | N/A |
9/30/2021 | 0 | -64 | -49 | -49 | N/A |
6/30/2021 | 0 | -47 | -40 | -40 | N/A |
3/31/2021 | 0 | -37 | -36 | -36 | N/A |
12/31/2020 | 0 | -32 | -30 | -30 | N/A |
9/30/2020 | 0 | -34 | -30 | -30 | N/A |
6/30/2020 | 0 | -35 | -32 | -32 | N/A |
3/31/2020 | 0 | -33 | -29 | -29 | N/A |
12/31/2019 | 0 | -26 | -21 | -21 | N/A |
9/30/2019 | 0 | -18 | -14 | -14 | N/A |
6/30/2019 | 0 | -14 | -9 | -9 | N/A |
3/31/2019 | 0 | -9 | -8 | -8 | N/A |
12/31/2018 | 0 | -7 | -7 | -7 | N/A |
9/30/2018 | 0 | -6 | -7 | -7 | N/A |
6/30/2018 | 0 | -5 | -6 | -6 | N/A |
3/31/2018 | 0 | -4 | -5 | -5 | N/A |
12/31/2017 | 0 | -1 | -5 | -3 | N/A |
9/30/2017 | 0 | -1 | -4 | -3 | N/A |
6/30/2017 | 1 | 0 | -3 | -2 | N/A |
3/31/2017 | 1 | 0 | -3 | -2 | N/A |
12/31/2016 | 1 | -2 | N/A | -2 | N/A |
9/30/2016 | 3 | -1 | N/A | -2 | N/A |
6/30/2016 | 3 | 0 | N/A | -2 | N/A |
3/31/2016 | 3 | 0 | N/A | -2 | N/A |
12/31/2015 | 3 | 0 | N/A | -2 | N/A |
9/30/2015 | 2 | 0 | N/A | -2 | N/A |
6/30/2015 | 2 | -1 | N/A | -2 | N/A |
3/31/2015 | 2 | -1 | N/A | -2 | N/A |
12/31/2014 | 2 | -2 | N/A | -3 | N/A |
9/30/2014 | 2 | -2 | N/A | -3 | N/A |
6/30/2014 | 2 | -1 | N/A | -4 | N/A |
3/31/2014 | 2 | -1 | N/A | -3 | N/A |
12/31/2013 | 2 | -1 | N/A | -3 | N/A |
9/30/2013 | 2 | -1 | N/A | -3 | N/A |
6/30/2013 | 2 | -2 | N/A | -3 | N/A |
3/31/2013 | 2 | -10 | N/A | -3 | N/A |
12/31/2012 | 2 | -13 | N/A | -3 | N/A |
9/30/2012 | 3 | -15 | N/A | -2 | N/A |
6/30/2012 | 3 | -14 | N/A | -2 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BLU is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BLU is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BLU is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BLU's revenue (69% per year) is forecast to grow faster than the US market (8.1% per year).
High Growth Revenue: BLU's revenue (69% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BLU's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2023/06/28 05:06 |
End of Day Share Price | 2023/06/28 00:00 |
Earnings | 2023/03/31 |
Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
BELLUS Health Inc. is covered by 12 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Brian Skorney | Baird |
Justin Zelin | BTIG |
Pooya Hemami | Edison Investment Research |